About Beam Therapeutics
Beam Therapeutics is a company based in Cambridge (United States) founded in 2017 by Keith Joung and David Liu.. Beam Therapeutics has raised $222 million across 4 funding rounds from investors including Sana Biotechnology, Arch Venture Partners and Eight Roads Ventures. The company has 483 employees as of December 31, 2024. Beam Therapeutics has completed 1 acquisition, including GuideTX. Beam Therapeutics offers products and services including Base Editing Technology. Beam Therapeutics operates in a competitive market with competitors including eGenesis, Korro Bio, Editas Medicine, Intellia Therapeutics and Metagenomi, among others.
- Headquarter Cambridge, United States
- Employees 483 as on 31 Dec, 2024
- Founders Keith Joung, David Liu
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Beam Therapeutics Inc.
-
Annual Revenue
$63.52 M-83.18as on Dec 31, 2024
-
Net Profit
$-376.74 M-184.28as on Dec 31, 2024
-
EBITDA
$-393.64 M-151.57as on Dec 31, 2024
-
Total Equity Funding
$222 M (USD)
in 4 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Oct 19, 2021
-
Investors
Sana Biotechnology
& 8 more
-
Employee Count
483
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Beam Therapeutics
Beam Therapeutics is a publicly listed company on the NASDAQ with ticker symbol BEAM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Beam Therapeutics
Beam Therapeutics offers a comprehensive portfolio of products and services, including Base Editing Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Precision tool for modifying DNA bases in genetic therapies
Unlock access to complete
Unlock access to complete
Leadership Team
48 people
Software Development Team
36 people
Senior Team
27 people
Product Management Team
18 people
Operations Team
11 people
Finance and Accounting
9 people
Legal and Compliance
8 people
Principal Team
7 people
Unlock access to complete
Funding Insights of Beam Therapeutics
Beam Therapeutics has successfully raised a total of $222M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $50.0M
-
First Round
First Round
(14 May 2018)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2021 | Amount | Post-IPO - Beam Therapeutics | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Beam Therapeutics | Valuation |
investors |
|
| Mar, 2019 | Amount | Series B - Beam Therapeutics | Valuation | Altitude Life Science Ventures , Google Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Beam Therapeutics
Beam Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Sana Biotechnology, Arch Venture Partners and Eight Roads Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage life sciences sectors focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Beam Therapeutics
Beam Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include GuideTX. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Technology for DNA and RNA delivery to targets is provided.
|
2019 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Beam Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Beam Therapeutics Comparisons
Competitors of Beam Therapeutics
Beam Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as eGenesis, Korro Bio, Editas Medicine, Intellia Therapeutics and Metagenomi, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| domain | founded_year | HQ Location |
Therapeutics using CRISPR/Cas9 are developed for various diseases.
|
|
| domain | founded_year | HQ Location |
Next-generation gene editing tools are developed for drug enhancement.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Beam Therapeutics
Frequently Asked Questions about Beam Therapeutics
When was Beam Therapeutics founded?
Beam Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Beam Therapeutics located?
Beam Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Beam Therapeutics?
John Evans is the current CEO of Beam Therapeutics.
Is Beam Therapeutics a funded company?
Beam Therapeutics is a funded company, having raised a total of $222M across 4 funding rounds to date. The company's 1st funding round was a Series B of $135M, raised on May 14, 2018.
How many employees does Beam Therapeutics have?
As of Dec 31, 2024, the latest employee count at Beam Therapeutics is 483.
What is the annual revenue of Beam Therapeutics?
Annual revenue of Beam Therapeutics is $63.52M as on Dec 31, 2024.
What does Beam Therapeutics do?
Beam Therapeutics was founded in 2017 in Cambridge, United States, within the biotechnology sector. Gene therapies are developed using CRISPR base editing technology to address conditions including sickle cell disease, thalassemia, leukemia, liver disorders, and ocular diseases. Specific base pairs in DNA or RNA are targeted and edited to correct point mutations, with operations focused on advancing these treatments through research and development.
Who are the top competitors of Beam Therapeutics?
Beam Therapeutics's top competitors include eGenesis, Tessera Therapeutics and Korro Bio.
What products or services does Beam Therapeutics offer?
Beam Therapeutics offers Base Editing Technology.
Is Beam Therapeutics publicly traded?
Yes, Beam Therapeutics is publicly traded on NASDAQ under the ticker symbol BEAM.
How many acquisitions has Beam Therapeutics made?
Beam Therapeutics has made 1 acquisition, including GuideTX.
Who are Beam Therapeutics's investors?
Beam Therapeutics has 9 investors. Key investors include Sana Biotechnology, Arch Venture Partners, Eight Roads Ventures, Altitude Life Science Ventures, and Google Ventures.
What is Beam Therapeutics's ticker symbol?
The ticker symbol of Beam Therapeutics is BEAM on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.